X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5812) 5812
Publication (846) 846
Book Review (76) 76
Book Chapter (26) 26
Conference Proceeding (9) 9
Newspaper Article (8) 8
Dissertation (7) 7
Magazine Article (7) 7
Trade Publication Article (5) 5
Book / eBook (1) 1
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3458) 3458
immunotherapy (3057) 3057
oncology (2567) 2567
humans (2324) 2324
pd-1 (2254) 2254
cancer (2135) 2135
pd-1 protein (1440) 1440
melanoma (1401) 1401
nivolumab (1385) 1385
immunology (1317) 1317
tumors (1316) 1316
lymphocytes (1173) 1173
pd-1 blockade (1140) 1140
immune checkpoint (1076) 1076
apoptosis (1029) 1029
lymphocytes t (995) 995
pembrolizumab (981) 981
pd-l1 (977) 977
female (946) 946
chemotherapy (904) 904
patients (894) 894
animals (891) 891
ipilimumab (889) 889
care and treatment (884) 884
t cells (861) 861
expression (857) 857
metastasis (821) 821
pd-l1 protein (821) 821
male (798) 798
lung cancer (674) 674
programmed cell death 1 receptor - antagonists & inhibitors (666) 666
cancer therapies (660) 660
middle aged (616) 616
antigens (608) 608
safety (602) 602
blockade (600) 600
research (599) 599
cell death (587) 587
open-label (587) 587
ligands (585) 585
therapy (585) 585
clinical trials (584) 584
t-cells (579) 579
immune system (557) 557
survival (554) 554
ctla-4 (547) 547
article (546) 546
mice (538) 538
analysis (535) 535
aged (526) 526
metastases (523) 523
cytotoxicity (517) 517
anti-pd-1 (516) 516
health aspects (501) 501
immune response (482) 482
biomarkers (481) 481
metastatic melanoma (476) 476
immunotherapy - methods (460) 460
review (460) 460
antibodies, monoclonal - therapeutic use (451) 451
adult (446) 446
programmed cell death 1 receptor - immunology (442) 442
mutation (431) 431
medical research (429) 429
antibodies (428) 428
gene expression (423) 423
medicine & public health (423) 423
cell biology (404) 404
cell lung-cancer (403) 403
cd8 antigen (393) 393
prognosis (392) 392
medical prognosis (384) 384
medicine, research & experimental (374) 374
neoplasms. tumors. oncology. including cancer and carcinogens (372) 372
tumor-infiltrating lymphocytes (366) 366
treatment outcome (365) 365
drug therapy (364) 364
dendritic cells (363) 363
antineoplastic agents - therapeutic use (358) 358
activation (355) 355
neoplasms - immunology (346) 346
programmed cell death 1 receptor - metabolism (345) 345
docetaxel (344) 344
proteins (343) 343
cytokines (340) 340
usage (338) 338
b7-h1 antigen - antagonists & inhibitors (333) 333
ctla-4 protein (332) 332
immune checkpoint inhibitors (325) 325
immunity (325) 325
monoclonal antibodies (322) 322
hematology (320) 320
tumor microenvironment (314) 314
multidisciplinary sciences (311) 311
b7-h1 antigen - metabolism (310) 310
immunohistochemistry (305) 305
advanced melanoma (300) 300
antibody (297) 297
inhibitors (296) 296
regulatory t-cells (295) 295
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5683) 5683
German (56) 56
French (51) 51
Chinese (18) 18
Russian (12) 12
Japanese (11) 11
Korean (8) 8
Spanish (3) 3
Polish (2) 2
Dutch (1) 1
Hungarian (1) 1
Slovenian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 07/2017, Volume 35, Issue 19, pp. 2193 - 2202
Purpose Data suggest that DNA damage by poly (ADP-ribose) polymerase inhibition and/or reduced vascular endothelial growth factor signaling by vascular... 
SENSITIVE OVARIAN-CANCER | MULTICENTER | ANTI-PD-1 | ONCOLOGY | ANTITUMOR-ACTIVITY | NIVOLUMAB | Piperazines - administration & dosage | Vascular Endothelial Growth Factor Receptor-1 - antagonists & inhibitors | Phthalazines - pharmacokinetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Quinazolines - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Genital Neoplasms, Female - drug therapy | Adult | Female | Quinazolines - administration & dosage | Piperazines - pharmacokinetics | Phthalazines - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Genital Neoplasms, Female - immunology | B7-H1 Antigen - immunology | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Genital Neoplasms, Female - metabolism | Protein Kinase Inhibitors - administration & dosage | B7-H1 Antigen - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | B7-H1 Antigen - biosynthesis | Quinazolines - adverse effects | Aged | Genital Neoplasms, Female - pathology | Phthalazines - adverse effects | Lymphocytes, Tumor-Infiltrating - immunology | Index Medicus | Phase I and Clinical Pharmacology | Combined Modality | Breast Cancer | ORIGINAL REPORTS
Journal Article
Current Oncology Reports, ISSN 1523-3790, 9/2018, Volume 20, Issue 9, pp. 1 - 12
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 08/2018, Volume 13, Issue 8, pp. 1138 - 1145
Journal Article
International Journal of Cancer, ISSN 0020-7136, 07/2018, Volume 143, Issue 1, pp. 45 - 51
Journal Article
American Journal of Clinical Dermatology, ISSN 1175-0561, 6/2018, Volume 19, Issue 3, pp. 345 - 361
Journal Article
Cancer Discovery, ISSN 2159-8274, 07/2018, Volume 8, Issue 7, pp. 822 - 835
KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct... 
CTLA-4 BLOCKADE | CANCER-PATIENTS | MELANOMA | ONCOLOGY | COOCCURRING GENOMIC ALTERATIONS | OPEN-LABEL | RANDOMIZED CONTROLLED-TRIAL | NIVOLUMAB | LKB1 LOSS | DOCETAXEL | TUMOR MICROENVIRONMENT | non-small cell lung cancer | PD-1 blockade | STK11 | KRAS | LKB1 | lung adenocarcinoma
Journal Article
Cancer Research, ISSN 0008-5472, 10/2017, Volume 77, Issue 20, pp. 5639 - 5651
Journal Article
Cancer Cell, ISSN 1535-6108, 06/2017, Volume 31, Issue 6, pp. 848 - 848.e1
Journal Article
Best Practice & Research Clinical Rheumatology, ISSN 1521-6942, 12/2018, Volume 32, Issue 6, pp. 781 - 802
Checkpoint inhibitors (CI) have revolutionized the management of many cancers but can result in immune-related adverse events (IRAE). In this chapter, we... 
Myositis | Immune checkpoint inhibitor | Immune-related adverse event | Immunotherapy | Inflammatory arthritis | PD-1 BLOCKADE | POLYMYALGIA-RHEUMATICA | COMBINED NIVOLUMAB | MONOCLONAL-ANTIBODY | CANCER-IMMUNOTHERAPY | RHEUMATOLOGY | METASTATIC MELANOMA | INDUCED SARCOIDOSIS | IPILIMUMAB THERAPY | TO-LYMPHOCYTE RATIO | ADVERSE EVENTS | Autoimmunity | Arthritis | Analysis
Journal Article
Journal Article